We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Lateral Flow Tests Detect COVID-19 with Similar Accuracy to Laboratory-Based PCR Tests When Used at Onset of Symptoms

By LabMedica International staff writers
Posted on 15 Jul 2021
Print article
Illustration
Illustration
A new study has found that lateral flow tests detect COVID-19 with similar accuracy to laboratory-based PCR tests, providing they are used at the onset of infection and soon after symptoms start.

The finding by researchers at Queen Mary University of London (London, UK), University of Oxford (Oxford, UK), Institute for Advanced Studies (Vienna, Austria), and the Medical University of Graz (Graz, Austria) could be pivotal to strategies looking to tackle the next phase of the pandemic, especially as timely and rapid testing becomes even more important once restrictions are lifted.

Lateral flow tests are cheaper and produce a result in just 30 minutes - much faster than the time it takes to receive a PCR test result, which can take 1-3 days. As part of the study, over 2,500 people with mild to moderate flu-like symptoms were assessed by GPs in the district of Liezen (population 79,652), Austria, between October 22 and November 30, 2020 and tested for viral antigen using lateral flow tests. Those who were suspected to have COVID-19 were also tested using a PCR test. The lateral flow tests detected more than 95% of the cases found by PCR, and correctly identified 89% of cases as negative.

The study was the first to compare lateral flow and PCR testing on the same group of people on a large scale. It also included the variables of a real-world setting: five different brands of test kit, three laboratories, and professional swabbing offered at 20 GP practices. In summary, the study provides evidence that lateral flow tests can accurately detect SARS-CoV-2 infection as an alternative to PCR testing among symptomatic patients in a real-life primary care setting across a large geographical area.

“Previous studies have suggested lateral flow tests may be less sensitive than PCR in detecting COVID-19, particularly among asymptomatic individuals and during the early or late stage of an infection when the viral load is lowest. But we have found that in patients who are newly symptomatic, the two testing methods have similar levels of accuracy,” said study author Dr Werner Leber from Queen Mary University of London. “Countries are considering using lateral flow tests to manage future waves of the pandemic. Our findings support this move, but ensuring tests are properly administered should be integral to any strategy.”

“In our study, both shorter duration of symptoms and higher viral load were significantly associated with positive lateral flow tests. This highlights the necessity of testing at early infection with lateral flow tests, and shows that in patients who are newly symptomatic, the two testing methods have similar levels of accuracy,” added Dr. Jasmina Panovska-Griffiths from the Big Data Institute and The Queen’s College at University of Oxford. “Our study is the first study to demonstrate that point-of-care antigen testing using lateral flow tests combined with clinical assessment of symptomatic patients can rapidly and accurately detect SARS-CoV-2 infection in primary care.”

Related Links:
Queen Mary University of London
University of Oxford
Institute for Advanced Studies
Medical University of Graz


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.